Articles tagged with Tau Proteins
A study examining nearly 300 clinically normal adults found that women showed more tau deposits in the brain than men, associated with greater Aβ plaque deposits, supporting potential reasons for differences in AD risk between men and women. The findings may be limited by the study population's age and demographic characteristics.
A new study finds that sleep deprivation increases tau levels in the brain, a key protein associated with neurodegeneration and Alzheimer's disease. The researchers suggest optimizing the sleep-wake cycle as a potential treatment target to prevent Alzheimer's.
A recent study published in Science has found that sleep deprivation increases levels of the key Alzheimer's protein tau, leading to accelerated brain damage and dementia. In mice and people, researchers discovered that disrupted sleep causes tau tangles to spread through the brain, a hallmark of Alzheimer's disease.
A study from Massachusetts General Hospital reveals that tau protein and amyloid-beta interact to impair brain function. Elevated tau levels were associated with reduced neural activity, regardless of tangle formation.
A new study found that certain neurons protect themselves from Alzheimer's by clearing toxic tau proteins, which accumulate in sluggish cells. The discovery suggests new treatment possibilities to support natural defense mechanisms against neurodegenerative diseases.
Excitatory neurons are more susceptible to abnormal tau protein accumulation, a key factor in Alzheimer's disease progression. The study identifies genetic differences between excitatory and inhibitory neurons that may explain their vulnerability.
Researchers have identified three promising radiopharmaceuticals that bind to tau tangles, a protein associated with neurodegenerative diseases. The tracers were tested in patients with Alzheimer's disease and found to show promise in measuring tau protein accumulation.
A recent study by the University of Helsinki reveals that pathological tau triggers a safety valve mechanism in cell membranes, leading to accelerated neuronal cell death and loss of synapses. Omega-3 fatty acids have been found to modify the microstructure of cell membranes, capturing tau aggregates within cells.
Researchers have found that tau protein interferes with the nucleus's ability to communicate with the cell, disrupting the function of the nuclear pore complex. This alteration accelerates tau aggregation and neurofibrillary tangle formation, leading to neural dysfunction and death in Alzheimer's disease.
Researchers have discovered a signal pathway within cells that could stop degeneration and improve learning and memory in affected patients. The study also invented a potential drug to target tauopathies, a class of diseases caused by misfolding of the tau protein.
New study by Drexel University researchers suggests that tau protein allows microtubules to grow and remain dynamic. This challenges the widely-held theory that tau stabilizes microtubules, which is critical for cognitive function.
Researchers discovered that tau protein mutations can increase cancer risk by up to 3.72 times, highlighting a new association between neurodegenerative disorders and cancer. The study's findings suggest that clinicians should monitor patients with tau mutations for their cancer risk, in addition to attending to neurodegeneration.
Researchers found that tau production and secretion from nerve cells is an active process in the natural course of Alzheimer's disease. This may explain why experimental treatments targeting tau have had disappointing results. The study provides new insights into the role of tau kinetics in neurodegenerative diseases.
A study investigated tau phosphorylation-related targets for Alzheimer's disease treatment, focusing on four kinases and one phosphatase. The model suggests the role of each enzyme in AD pathogenesis and identifies potential targets for therapy. This work builds upon InSysBio's quantitative systems pharmacology (QSP) modeling approach.
A study published in the journal Brain uses a combination of imaging techniques to examine tau build-up in patients with Alzheimer's disease and progressive supranuclear palsy. The findings support the transneuronal spread hypothesis, suggesting that tau starts in one place and spreads throughout the brain.
Researchers have developed small shining molecules that can recognize specific proteins in the brain, such as amyloid beta and tau. These molecules emit light at different wavelengths when bound to their target protein, enabling potential diagnostic tools for neurodegenerative diseases.
The compound anle138b was shown to close harmful openings in the membrane of nerve cells and induce conformational changes that modify pore conductivity. Treatment with anle138b normalized brain activity and improved learning ability in mice affected by Alzheimer's disease, regardless of when treatment started.
Researchers discovered that Tau protein interacts with and disrupts cell membranes, forming toxic complexes that induce neuronal toxicity. The complexes are made up of Tau proteins and phospholipids from the membrane, and can be taken up by neurons more readily than the fibril form of the protein.
A unique model for Alzheimer's disease has been developed, suggesting a new approach for treating the condition. By reducing stress granule proteins, nerve cell health and memory can be improved.
Researchers at UNC School of Medicine have discovered a damaging cascade of events inside brain cells that contribute to Alzheimer's disease. The study shows that amyloid beta protein can trigger an inflammatory response in immune cells, leading to the formation of bead-like structures filled with abnormal tau protein.
Scientists discover tau protein can form compact droplets with RNA, creating conditions for aggregation. The novel state highly concentrates tau and makes it vulnerable to fibril formation.
A novel property of tau protein has been identified, which may reveal a new step in the formation of pathological tau aggregates. The protein can condense into a compact droplet in a complex with RNA, retaining its liquid properties and creating conditions for vulnerability to aggregation.
Researchers develop rhodanine-based compounds to solubilize poorly water-soluble drugs, inhibiting tau protein aggregation and improving cell viability. The formulation additives preserve drug efficacy and activity, offering opportunities for early-stage drug testing.
Researchers developed peptide-polymer conjugates to enhance water solubility of poorly soluble anti-Alzheimer drugs. The conjugates showed inhibitory activity against Tau protein aggregation, improving cell viability and reducing apoptosis in AD models.
Researchers discover how tau prevents synaptic transmission in nerve cells, even before forming tangles, which disrupts brain cell function. This mechanism may pave the way for a treatment to prevent death of nerve cells.
A team of scientists has discovered an antibody that can measure tau levels in the blood, which accurately reflects brain damage. This breakthrough could lead to a non-invasive test for tau-based diseases, monitoring disease progression, and measuring treatment effectiveness.
Nagoya University researchers have discovered a link between RNA binding proteins FUS and SFPQ and the development of frontotemporal lobar degeneration, a type of dementia that starts in middle age. The study suggests that rebalancing the tau protein ratio may prevent FTLD-like phenotypes.
Researchers found a potential treatment for Alzheimer's disease and other neurodegenerative disorders using a designer compound that prevents tau protein damage. The compound, called tau antisense oligonucleotides, was shown to reverse brain injury in mice and monkeys.
Researchers develop antisense oligonucleotide to lower tau protein levels in mice, reversing neurological damage and improving survival. The treatment also shows promise in monkeys, suggesting a potential therapeutic approach for Alzheimer's and other tau-related diseases.
USP9 gene may provide new starting point for developing active ingredients to treat Alzheimer's disease. The researchers found that USP9 has an indirect influence on tau protein, which is believed to play a significant role in the onset of Alzheimer's disease.
Researchers identified a protein called kinase p38γ that assists protective phosphorylation of tau and interferes with amyloid-beta toxicity. Introducing the protein into mice brains prevented memory deficits associated with Alzheimer's disease.
Researchers developed an improved animal model of Alzheimer's disease using tau protein isolated from patient brains. The model replicates the formation and spread of brain fibrils associated with AD, offering new opportunities for investigating therapies to stop or slow their progression.
Researchers analyzed blood plasma levels of tau protein in patients with early onset psychosis (EOP) aged 18 and under, finding higher levels than controls. The study suggests altered tau protein metabolism in EOP, which may have implications for understanding the pathophysiology and developing new treatment strategies.
Researchers found that the cutting of tau by caspase-2 may play a critical role in the disordered brain circuit function of tauopathies. Blocking caspase-2 activity restored some learning and memory deficits in animal models, suggesting reversible cognitive loss.
Researchers have identified a new target for treating neurodegenerative diseases: Rolofylline, which alleviates learning and memory deficits in mice with aberrant Tau proteins. The drug re-establishes neuronal activity despite pathological Tau aggregates.
A newly discovered pathway in Alzheimer's disease may provide new treatment approaches by targeting the formation of tau-stress granules. Reducing key stress granule proteins prevents tau aggregation and nerve cell degeneration.
Researchers at Gladstone Institutes found that increasing levels of protein tau may reverse cognitive deficits caused by Alzheimer's disease. They discovered that tau disrupts memory in models of Alzheimer's disease by depleting protein KIBRA, which is critical for memory formation.
Researchers used PET scans to study the progressive stages of Alzheimer's disease in cognitively normal adults, tracking tau protein accumulation in the brain. The findings suggest that tau imaging could become an important tool in developing therapeutic approaches targeting either amyloid or tau, depending on the disease stage.
A novel therapeutic approach has been developed to target the monomeric Tau protein, reducing its misfolding and aggregation that leads to Alzheimer's and other neurodegenerative diseases. The study identified small molecule drug candidates capable of maintaining native function and preventing disease onset.
A recent study published in Neuron highlights a novel role for the appoptosin protein in initiating tau aggregation, a key component of brain lesions. Elevated levels of appoptosin increase caspase-mediated tau cleavage, leading to synaptic dysfunction and progressive deterioration of the central nervous system.
A study by UCSB scientists examined the unique properties of tau, a critical protein in neurons that can form clumps associated with Alzheimer's disease. Researchers found that exposing tau to certain chemicals, such as urea, could prevent aggregation, while another compound, TMAO, accelerated it.
A new experimental PET tracer effectively diagnoses chronic traumatic encephalopathy (CTE) while patients are still alive. The technology differentiates CTE from other forms of dementia, enabling estimates of prevalence and risk. This breakthrough improves diagnosis and treatment for athletes and others exposed to repeated head trauma.
Research found that AMPK regulates tau protein phosphorylation, reduces amyloidogenesis, and modulates inflammatory cytokines in postoperative cognitive dysfunction rats. The involvement of AMPK and inflammatory factors is considered a critical accommodation to postoperative cognitive dysfunction.
A new gene variant, PLXNA4, has been linked to an increased risk of developing Alzheimer's disease. The study found that this gene affects the processing of tau protein, a key hallmark of the disease. This discovery may lead to the development of targeted drug treatments for AD.
The study found that AMPK and inflammatory cytokines play a significant role in postoperative cognitive dysfunction. AMPK regulates tau protein phosphorylation, reducing amyloidogenesis in neurons.
Researchers at UTMB have discovered a way to remove the toxic oligomeric tau protein, which can slow down the progression of dementia caused by Alzheimer's disease. The treatment, TOMA antibody, protects brain cells from tau toxic aggregates and improves cognitive function.
Researchers found that transient brain ischemia induces hyperphosphorylation of tau protein and alters its interaction with glycogen synthase kinase (GSK)-3β and protein phosphatase 2A. Lithium chloride's neuroprotective function may depend on regulating tau phosphorylation during cerebral ischemia.
Researchers at TUM have found that the heat shock protein Hsp90 binds to prefolded tau proteins, which are characteristic of Alzheimer's disease. This discovery provides important insights into the mechanisms underlying the disease and may lead to new therapies.
Researchers developed a new class of imaging agents to visualize tau protein aggregates, a hallmark of Alzheimer's disease. The use of these fluorescent compounds in PET tests provides valuable information on brain regions at risk for tau-induced neuronal death.
A University of South Florida-led study suggests that the stress-related protein FKBP51 contributes to the acceleration of Alzheimer's disease. The research found that FKBP51 levels increase with age and partner with Hsp90 to make tau more toxic, leading to brain cell death.
Eva-Maria and Eckhard Mandelkow have made significant progress in understanding the role of tau protein in Alzheimer's disease. Their findings suggest that modifications to normal tau proteins can destroy synapses and lead to cognitive decline, offering a potential target for therapy.
Researchers have developed a new approach to screening potential treatments for Alzheimer's disease using the C. elegans worm model. The study identified six compounds capable of alleviating tau-induced behavioral abnormalities in the worm model, as well as azaperone treatment, which can decrease abnormal tau accumulation.
Researchers have discovered how methylene blue modifies tau proteins, which aggregate in Alzheimer's disease. The study reveals that methylene blue deactivates molecular residues promoting bonding and acts as a spacer to keep proteins apart, leading to potential treatment strategies.
Researchers have developed a new technique to identify abnormal tau proteins associated with repetitive head injuries, potentially leading to earlier diagnosis and tracking of brain disorders. The study used PET scans to detect elevated levels of FDDNP in the brains of five retired NFL players.
Researchers have demonstrated that obesity aggravates disorders associated with tau protein in mice, contradicting previous assumptions. The study suggests environmental factors contribute to the development of Alzheimer's disease, rather than just metabolic conditions.
Abnormalities in mitochondrial length promote neurodegenerative diseases like Alzheimer's, while optimal length is essential for maintaining cellular health. The study reveals a complex interplay between proteins DRP1 and actin, which are affected by defective tau protein.
Myoglobin's motion is essential for its biological function, and neutron scattering shows it can perform without water. This discovery makes proteins a viable material for new wound dressings or chemical gas sensors.
Researchers at Boston University School of Medicine have identified a new group of RNA-binding proteins that accumulate in the brains of patients with Alzheimer's disease. These findings may lead to novel diagnostic approaches and a better understanding of the disease progression.
Researchers at the University of California, San Diego, found that chronic stress triggers the production and accumulation of insoluble tau protein aggregates inside brain cells, similar to neurofibrillary tangles. This may explain why people prone to stress are more likely to develop sporadic Alzheimer's disease.
New research reveals that tau oligomers, smaller structures formed before neurofibrillary tangles, are the most toxic entities in Alzheimer's. High levels of tau oligomers have been found in some Alzheimer's brains, and their presence has been linked to various biochemical behaviors and structures.